• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Anaptysbio Inc (NQ: ANAB )

    21.63 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Anaptysbio Inc

    < Previous 1 2 Next >
    Anaptys Announces Participation in September Investor Conferences
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
    Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi 
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Named a BioSpace 2024 Best Places to Work Winner
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Participation in November Investor Conferences
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Argenx's 28% Surge & Promising Product Propel Investor Confidence
    Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
    Via MarketBeat
    AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces Participation in Upcoming Investor Conferences
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces Stock Repurchase Plan
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
    From AnaptysBio, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.